Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rituximab

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

China flag thumb

Roche drawn into Chinese probe into pharma

State authorities visit regional offices of Swiss company

Roche - Basel

Roche and Merck boost manufacturing capacity

Pharma companies invest in European facilities

EU flag

AbbVie’s hep C combo gets priority review in Europe

EMA to fast track drug for use in hard-to-treat genotype 1 strain of HCV

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links